No insider purchase over the last 90 days. The latest, by SYCOFF DREW, was filed 24 Apr 2024.
We have very little insider data for GlucoTrack, Inc. so far: the most recent filing dates from 7 October 2025. With so few records, no pattern can be drawn yet. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
FY ended December 2025 · cache
25 of 46 declarations
GlucoTrack, Inc. is a company focused on developing blood glucose monitoring technologies. It specializes in non-invasive solutions for individuals with diabetes.
Purchases our model currently ranks for the recommendations list.
All recommendations| Fiscal year end | Revenue | Net income | Diluted EPS | Filing |
|---|---|---|---|---|
| Dec 2019 | n.d. | 3.5 m USD | -0.02 USD | 10-K |
| Dec 2018 | 43,488 USD | -6.7 m USD | -4.74 USD | 10-K |
| Dec 2017 | n.d. | 10.3 m USD | -1.87 USD | 10-K |
| Dec 2016 | 611,689 USD | -5.4 m USD | -1.08 USD | 10-K |
| Dec 2015 | 143,167 USD | -5.8 m USD | -1.15 USD | 10-K |
Amounts in USD, as filed (forms 10-K, 20-F or 40-F). Source: SEC EDGAR.